×

Register now for full access to all the content

First Name
Last Name
Company Name
Title
Country
Thank you for registering!
Error - something went wrong!

PAREXEL - Albert Liou Discusses the Drug Development Landscape in Korea

May 26, 2015
Korea is becoming a global hub for many reasons. There is a good infrastructure, good regulatory system, and there also there are a lot of professionals with good talent in this country. Since 2000’s, the government has made great reforms to the regulatory systems. For instance, GCP, global GCP has been implemented in Korea. And the Korean government has separated R&D and NDA processing. That makes clinical trials much easier to get an approval. And also they implemented 60-days for R&D review period. All of this makes the regulatory systems friendlier for clinical research and also aligned with the global systems. And another thing, hospital and medical centers, have made a lot of improvement since 2000’s. The government has put in a lot of funding to improve the infrastructure and also train a lot of good investigators in this area. And as a result - this makes Korea become a very important clinical research hub in Asia.
Previous Video
PAREXEL - Paul Evans Discusses the Challenges of Patient Recruitment
PAREXEL - Paul Evans Discusses the Challenges of Patient Recruitment

Patient recruitment today is more challenging than ever. If you think about clinical trials, they don’t tak...

Next Video
PAREXEL - Roland Andersson, SVP, Discusses Investing Trends and Emerging Biopharmaceutical Companies
PAREXEL - Roland Andersson, SVP, Discusses Investing Trends and Emerging Biopharmaceutical Companies

PAREXEL helps position emerging Biopharmaceutical companies by providing them with advice and capabilities....